Related Experiment Video
Updated: Mar 14, 2026
Introduction of an Integrated Pathology Image Management, Artificial Intelligence, and Reporting System
Published on: July 11, 2025
Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa
Yuxiao Zheng1, Yuan Huang1, Gong Cheng1
1State Key Laboratory of Reproductive Medicine, Department of Urology, First Affiliated Hospital of Nanjing Medical University, 300, Guangzhou Road, Nanjing, 210029 Jiangsu Province China.
Objective:
To develop a new score system for patients with prostate specific antigen (PSA) ranging from 4 to 20 ng/mL to improve the accuracy of prostate cancer (PCa) detection, and to evaluate it with receiver operating characteristic curve.
Methods:
A total of 797 patients (208 with prostate cancer) with total PSA 4-20 ng/mL who had undergone transrectal ultrasound (TRUS)-guided 12 + 1-core prostate biopsy during Sept. 2009-Jan. 2013 were retrospectively evaluated in the study. Age, PSA, fPSA, PV, f/T, PSAD, DRE findings and ultrasound findings were considered as predictive factors and tested by logistic regression. Predictors with P < 0.05 were selected to develop a new score system.
Results:
Age, PSA, PV, f/T, DRE findings, and hypoechoic in ultrasound were selected in our new score system. The risk of PCa increased with the score. From 0 to 6, the risk was 2.0, 8.4, 13.9, 33.5, 63.8, 75.0 and 100.0 % respectively. Area under curve (AUC) of our new score system was 0.804, which was significantly higher than The Prostate Cancer Risk Calculator by Stichting Wetenschappelijk Onderzoek Prostaatkanker (SWOP) (0.720, P = 0.002).
Conclusions:
We developed a new simple score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection.
